CB BENWAY: Open Payments
NPI 1295740744 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,662 in 87 payments from 15 companies in 2025. Trend: 2023 $1,423 · 2024 $1,383 · 2025 $1,662
Food & beverage: $1,662
| Company | Payments | Amount |
|---|---|---|
| Tris Pharma Inc | 14 | $331 |
| ABBVIE INC. | 15 | $227 |
| Alkermes, Inc. | 10 | $174 |
| Teva Pharmaceuticals USA, Inc. | 10 | $158 |
| E.R. Squibb & Sons, L.L.C. | 9 | $156 |
| Corium, LLC | 6 | $123 |
| Lundbeck LLC | 4 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
Products named: Dyanavel XR, VRAYLAR, ARISTADA, AUSTEDO XR, COBENFY, Azstarys, REXULTI, CAPLYTA.
Industry payments across MD — which companies pay providers there.
